Chemotherapy vs. immunotherapy for the treatment of Merkel cell carcinoma
In this interview, Paul Nghiem, MD, PhD, from the University of Washington, Seattle, WA, discusses the results of the Phase II trial investigating pembrolizumab as a first-line treatment for advanced ...
Author: VJOncology
Added: 08/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 13, 2018 Category: Cancer & Oncology Source Type: podcasts
ALL: recent immunotherapeutic developments
In this video, Ryan Cassaday, MD, of the University of Washington, Seattle, WA, gives an overview of recent developments in the field of acute lymphoblastic leukemia (ALL). He touches upon inotuzumab ...
Author: VJHemOnc
Added: 07/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Improving the SOC for ALL with inotuzumab
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ryan Cassaday, MD, of the University of Washington, Seattle, WA, discusses the INO-VATE trial (NCT015647...
Author: VJHemOnc
Added: 07/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Merkel Cell Carcinoma Needs to be Managed in Multidisciplinary Way | Oncology, Surgery, Radiation Therapy, Dermatology...
Paul Nghiem, MD, PhD, University of Washington, shares MCC Needs to be Managed in Multidisciplinary Way | Oncology, Surgery, Radiation Therapy, Dermatology, etc at ASCO 2018
Author: Annual-Meeting
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Patients Who Dont Respond to Checkpoint Therapy | Collaborating to Pick Apart Mechanisms of Resistance
Paul Nghiem, MD, PhD, University of Washington, shares Patients Who Dont Respond to Checkpoint Therapy | Collaborating to Pick Apart Mechanisms of Resistance at ASCO 2018
Author: Annual-Meeting
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Academic & Community Oncologists Must Collaborate | Accrue Trials to Develop New Therapies
Petros Grivas, MD, PhD, University of Washington talks about Academic & Community Oncologists Must Collaborate | Accrue Trials to Develop New Therapies at ASCO 2018
Author: Annual-Meeting
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Publish New Abstract Data Next Year | Complete Accrual of Estrogen Receptor Imaging
Hannah Linden, MD, University of Washington shares Publish New Abstract Data Next Year | Complete Accrual of Estrogen Receptor Imaging at ASCO 2018
Author: Annual-Meeting
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Dynamic Era of Changes for Urothelial Cancer | Data with FGFR Inhibitors, Antibody-Drug Conjugates
Petros Grivas, MD, PhD, University of Washington talks about Dynamic Era of Changes for Urothelial Cancer | Data with FGFR Inhibitors, Antibody-Drug Conjugates at ASCO 2018
Author: Annual-Meeting
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
The Point of Estrogen Receptor Imaging? | If Receptor Functions & Need Endocrine Therapy
Hannah Linden, MD, University of Washington shares The Point of Estrogen Receptor Imaging? | If Receptor Functions & Need Endocrine Therapy at ASCO 2018
Author: Annual-Meeting
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Whether Genomic Alterations Have Significance & #124; And/Or Predict Response to Individual Therapies
Petros Grivas, MD, PhD, University of Washington talks about Whether Genomic Alterations Have Significance | And-Or Predict Response to Individual Therapies at ASCO 2018
Author: Annual-Meeting
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
ER Imaging Not Ready for Commercial Use | Working Hard With Tracer Manufacturers
Hannah Linden, MD, University of Washington shares ER Imaging Not Ready for Commercial Use | Working Hard With Tracer Manufacturers at ASCO 2018
Author: Annual-Meeting
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Circulating Tumor DNA as a Putative Biomarker | For Patients with Advanced Urotelial Carcinoma
Petros Grivas, MD, PhD, University of Washington talks about Circulating Tumor DNA as a Putative Biomarker | For Patients with Advanced Urotelial Carcinoma at ASCO 2018
Author: Annual-Meeting
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Estrogen Receptor Imaging | Lobular Tumors Detectable by FES PET
Hannah Linden, MD, University of Washington shares Estrogen Receptor Imaging | Lobular Tumors Detectable by FES PET
Author: Annual-Meeting
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Collaborative Community Working to Understand MCC | Do Not Need Mutational Burden to Have Response
Paul Nghiem, MD, PhD, University of Washington, shares Collaborative Community Working to Understand MCC | Do Not Need Mutational Burden to Have Response at ASCO 2018
Author: Annual-Meeting
Added: 06/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Cannot Predict Who Responds to Immunotherapies | Response is 60% or More If therapy is Given First Line
Paul Nghiem, MD, PhD, University of Washington, shares Cannot Predict Who Responds to Immunotherapies | Response is 60% or More If therapy is Given First Line at ASCO 2018
Author: Annual-Meeting
Added: 06/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 9, 2018 Category: Cancer & Oncology Source Type: podcasts
